- Trial phase
- Approved
- Time to market
- Already on the market since 2017.
- Why 3/10
- Emflaza is already approved and commercialized with no pending regulatory decision (PDUFA, pivotal readout, or AdComm). The last FDA exclusivity expired in June 2026, and the drug faces multi-source generic competition. It is now a small and declining portion of PTC Therapeutics' revenue (about 7% of Q3 2026 total revenue), with the company's growth driven by its newer product Sephience.
Emflaza is a post-exclusivity asset in revenue decline with no upcoming binary catalyst. The key event to watch for this drug is the pace of revenue erosion in PTC's quarterly earnings reports, as generic competition continues to erode market share. For PTC Therapeutics overall, the focus has shifted to Sephience's commercial trajectory and the ST-920 Fabry gene therapy BLA submission expected in Q4 2026.
Price Chart
Executive Summary
Emflaza (deflazacort) is an FDA-approved corticosteroid for Duchenne muscular dystrophy, first approved in 2017 and marketed by PTC Therapeutics (PTCT). The drug faced its first generic competition in February 2024 when Aurobindo launched generic deflazacort tablets, followed by Tris Pharma's generic oral suspension. The last remaining FDA orphan-drug exclusivity (covering ages 2-5) expired in June 2026. Emflaza net product revenue has declined sharply from $36.4M in Q2 2025 to $24.6M in Q2 2026, and to $25.1M in Q3 2026. It now represents a small and shrinking fraction of PTC's business, which is pivoting to its PKU drug Sephience (sepiapterin) and a Fabry gene therapy acquisition.
How It Works
Emflaza is a corticosteroid (a type of steroid) that reduces inflammation and suppresses the immune system. It is used to preserve muscle strength and slow disease progression in Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle weakening. It is taken orally as a tablet or liquid suspension.
Trial Status
Emflaza was first approved by the FDA in February 2017 for DMD patients aged 5 and older. The label was expanded in June 2019 to include patients as young as 2 years old. It is an already-commercialized product with no ongoing pivotal trials.
The Two-Sided Case
Upcoming Catalysts
- No upcoming regulatory catalysts for Emflaza specifically. The drug faces ongoing generic erosion with no remaining FDA exclusivity.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PTC THERAPEUTICS, INC. 8-K PTCT ·Originating report